Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Biomarin Pharmaceuticals
(NQ:
BMRN
)
92.57
-1.27 (-1.35%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomarin Pharmaceuticals
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
BioMarin Receives European Commission's Conditional Marketing Authorization For Gene Therapy Candidate
August 24, 2022
The European Commission (EC) has granted conditional marketing authorization (CMA) to BioMarin Pharmaceutical’s (NASDAQ: BMRN) lead asset ROCTAVIAN (valoctocogene roxaparvovec) gene therapy for the...
Via
Benzinga
Hopeful Golden Cross Forms On Biomarin Pharmaceutical's Chart
August 09, 2022
If history is any guide, there may be good fortune ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "golden cross" has formed on its chart and, not surprisingly, this could be...
Via
Benzinga
Expert Ratings for Biomarin Pharmaceutical
August 04, 2022
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:
Via
Benzinga
BioMarin Lifts Annual Guidance On Better Than Expected Q2 Earnings
August 04, 2022
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Analyst Ratings for Biomarin Pharmaceutical
July 13, 2022
Within the last quarter, Biomarin Pharmaceutical (NASDAQ:BMRN) has observed the following analyst ratings:
Via
Benzinga
BioMarin Stock Dives As FDA Questions The Safety Of Its Gene Therapy
February 18, 2022
BioMarin needs to run additional testing in animal models for its PKU gene therapy.
Via
Investor's Business Daily
7 Undervalued Biotech Stocks to Buy Before They Boom
July 25, 2022
Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For July 13, 2022
July 13, 2022
Upgrades
Via
Benzinga
BioMarin Sells Priority Review Voucher For $110M
February 09, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) has agreed to sell the Rare Pediatric Disease Priority Review Voucher (PRV)
Via
Benzinga
Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them
July 11, 2022
Four pharmaceutical stocks, including three biotech movers, are making big moves.
Via
Investor's Business Daily
The Daily Biotech Pulse: Precision BioSciences Inks Gene Editing Pact, Athira Pharma's Alzheimer's Candidate Fails, Enanta Sues Pfizer Over COVID-19 Antiviral
June 22, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
What 4 Analyst Ratings Have To Say About Biomarin Pharmaceutical
June 13, 2022
Analysts have provided the following ratings for Biomarin Pharmaceutical (NASDAQ:BMRN) within the last quarter:
Via
Benzinga
9 Health Care Stocks With Whale Alerts In Today's Session
May 18, 2022
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...
Via
Benzinga
The Week Ahead In Biotech (May 8-14): Bausch Health Headlines Smid-Cap Earnings, Veru's Pre-EUA Meeting, Conference Presentations And More
May 09, 2022
Biotech stocks declined yet again in the week ending May 6, dragged lower by macroeconomic concerns following the Federal Reserve's 50-basis-point rate hike. The iShares Biotechnology ETF (NASDAQ:...
Via
Benzinga
BioMarin Achieves Record Q1 Sales Driven By Recently Approved Achondroplasia Therapy
April 28, 2022
Via
Benzinga
The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis
April 27, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Biomarin Pharmaceutical Earnings Preview
April 26, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 25, 2022
April 25, 2022
Via
Benzinga
10 Biggest Price Target Changes For Monday
April 25, 2022
Keybanc cut Salesforce, Inc. (NYSE: CRM) price target from $281 to $223. Salesforce shares fell 1.1% to $169.60 in pre-market trading.
Via
Benzinga
The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More
April 24, 2022
Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...
Via
Benzinga
A Bearish Sign Appears On Biomarin Pharmaceutical's Chart
April 21, 2022
If history is any guide, there may be trouble ahead for shares of Biomarin Pharmaceutical (NASDAQ:BMRN). A so-called "death cross" has formed on its chart and, not surprisingly, this could be bearish...
Via
Benzinga
7 Potential Biotech Stocks Buyout Targets in 2022
April 21, 2022
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company.
Via
InvestorPlace
The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine Company
February 24, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Appoints COO David Hering As Interim CEO Adagio Therapeutics, Inc., (...
Via
Benzinga
BioMarin Clocks Flat Q4 Sales Despite Erosion oF US Kuvan Market
February 24, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) reported a 1% Y/Y decrease in Q4 revenue to $449.8 million, beating the consensus estimate of $442.39 million. The decline...
Via
Benzinga
Recap: Biomarin Pharmaceutical Q4 Earnings
February 23, 2022
Biomarin Pharmaceutical (NASDAQ:BMRN) reported its Q4 earnings results on Wednesday, February 23, 2022 at 04:00 PM. Here's what investors need to know about the announcement....
Via
Benzinga
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
February 23, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase...
Via
Benzinga
FDA Asks For More Data To Resolve BioMarin's Gene Therapy Clinical Hold
February 18, 2022
BioMarin Pharmaceutical Inc (NASDAQ: BMRN) said that the FDA had requested additional information regarding the clinical hold on PHEARLESS Phase 1/2 study of BMN...
Via
Benzinga
Bear Market Bets In Biotech
February 07, 2022
Taken together, the SPDR S&P Biotech ETF easily broke below the long-term 200-week support for the first time since the pandemic originally hit the markets in March of 2020.
Via
Talk Markets
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
February 20, 2022
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front...
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.